IHS Customer Logins

Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.

Top Sites

Life Sciences Consulting

Advance your company’s footprint

Looking to price a new drug? Enter an emerging market?

We provide customized healthcare market analysis, reimbursement consulting and regulation solutions, pricing models, market entry strategies and single or multi-client studies to help you:

  • Size and seize market opportunities
  • Drive operational efficiencies and ROI
  • Optimize product and sales strategies
  • Evaluate the economic impact of business or policy decisions
  • Respond quickly to alternative outcomes and shocks

Advisory Services

Market Research
Demonstrate the potential of pharmaceuticals, biotechnology products, medical devices and care delivery patterns on patient health outcomes, medical costs, productivity and quality of life

Reimbursement Consulting
Identify and quantify key cost drivers to develop efficient, evidence-based estimates for reimbursement and prospective payment

Healthcare Pricing Models
Develop the optimal new drug price and market entry strategy

Market Entry Analysis
Receive continuous analysis, data and online tools covering technology, reimbursement, regulations, geographic/therapeutic segment scenarios

Single-Client Reports
Partner with us for customized research on business improvement and opportunity maximization strategies

Multi-Client Reports
Access customized research at less cost by participating in multi-client, syndicated market research that employs qualitative and quantitative surveys, market access scenarios and market analysis

Recent Projects

Integrating HTA Requirements into Oncology R&D Process

A pharmaceutical company needed recommendations for incorporating more HTA considerations into R&D decision-making.

We researched recent HTA decisions in Australia, US, United Kingdom, France, Germany, Italy and Spain in the client’s four therapeutic areas. Our detailed case studies identified the choice of trial design, trial comparator, patient group selection, primary and secondary outcome measures, strength of correlation between surrogate and final outcomes, traits of PRO evidence and studies, and a definition of clinical relevance.

We helped the client build user-friendly HTA "checklists". The client uses these checklists to ensure its R&D personnel factor HTA considerations into future planning.

Industry Success Stories


Blog Feed

Jul 28

A national cancer biomarker platform in Spain: When will it become a reality?

Whilst in the midst of research into our next multi-client study, Pathways to Precision Medicine: Navigating Payer Needs and Healthcare Systems through Molecular Diagnostics, I have encountered an ambitious proposal driven by two prominent medical societies- the Spanish Medical Oncology Society, SEOM, and the Spanish Soci..more

Jul 23

Transforming the Brazilian domestic pharma industry through PDPs

Among the markets in Latin America, Brazil is a leader in implementing a strategy of building up a domestic pharma industry through Productive Development Partnerships (PDPs). Last week, Brazil's ministry of health published a detailed report addressing the key  achievements of the PDPs and the prospects of the coming PDPs under new ..more

Jul 21

Maintaining focus in access to ARV medicines

‘and we’ve come so far’……The opening line of Take That’s 1995 classic chart toping hit Never Forget, could have fit perfectly for the launch of UNAIDS' latest report on the fight against HIV. There was also likely lots of slapping on the back as the rather extensive report laid down plenty of good news. We learnt that rates of new infection are now falli..more

Twitter Feed

Jul 21

Does the UNAIDS report whitewash over the very real funding crisis facing HIV treatment programs? http://t.co/flAGABKwsG


Filter Sort